Ulcerative Colitis

Drs Maia Kayal and David P. Hudesman provide an overview of the treatment landscape for the management of ulcerative colitis, highlighting efficacy and safety considerations.

An expert in gastroenterology shares her opinion on the current unmet needs and treatment challenges for patients with ulcerative colitis.

Endoscopic subscores can determine whether a patient is a suitable candidate for dose reduction.

Occult HBV infection prevalence in blood donors was 0.06% in low-endemicity countries, 0.12% in intermediate-endemicity countries, and 0.98% in high-endemicity countries.

Some noticeable presenting features included jaundice, vomiting, and diarrhea.

David P. Hudesman, MD, explains the differences between active and inactive disease and discusses the role of early ulcerative colitis detection in the optimization of patient care.

Maia Kayal, MD, and David P. Hudesman, MD, highlight the burden of disease and comment on the impact ulcerative colitis has on a patient’s quality of life.

Aluminum internalization was correlated with inflammatory status in Caco-2 cells.

Patients with IBS more commonly had provisional post-traumatic stress disorder, IE, and bowel problems following antibiotic use.

In the study, 2.10% of patients with Crohn’s disease and 1.90% of patients with ulcerative colitis were diagnosed with colorectal cancer.

Dr. David Hudesman expects drug developers to continue to target biologics for the treatment of IBD.

Repeated metabolite monitoring with subsequent dose optimization resulted in 67.2% of patients achieving therapeutic levels after 1 year and 87.8% of patients achieving steroid-free remission, while 90% had no therapy escalation or surgery.

There was a direct association between consuming honey, ham, seafood, organ meats, salt, fruits on trees, fruit juice, olive, and nuts and the probability of developing IBD and ulcerative colitis.

ALT fluctuations remained stable for patients with NAFLD throughout disease progression.

Overall, 61.8% of patients on their first biologic agent reported clinical remission.

Maia Kayal, MD, provides and overview of ulcerative colitis, highlighting symptomology, comorbidities, and the disease impact on patient’s quality of life.

The majority of cases do not require the modification of therapy because it does not negatively affect the course of COVID-19.

The overall prevalence of NAFLD was 40.6%, with every NAFLD patient having a BMI of at least 25.

Patients with obesity are at an increased risk of a number of diseases, including type 2 diabetes, IBD, and cardiovascular disease.

Regular activity impairment did not differ much between the different countries, but there was a significant difference in informal care and productivity loss observed.

The majority of cases were mild to moderate in severity.

The results are consistent with the original analysis from 2019, where the treatment resulted in a statistically significant effect on fibrosis improvement.

There was also a greater likelihood of vaccine recommendation observed from pediatricians compared to other medical specialties.

Patients with Crohn’s disease subtype, females, pediatric-onset IBD, young adult patients with IBD, and patients with short-duration IBD were all at a higher risk for suicide.

There was no association found between ever using metformin and the risk of either IBD, Crohn’s disease, or ulcerative colitis.

There was an increased odds of liver injury per exposure-mixture quartile increase for organochlorine pesticides, PBDEs) perfluoroalkyl substances, and metals.

Both the incidence and prevalence of the liver disease were higher in men than they were in women.

The majority of patients in the phase 2 study met the primary efficacy endpoint of a greater than or equal to a 10% reduction in total stool output over the 6-week efficacy evaluation period.

The mean values of stool scale form also increased in the kombucha cohort, while the control group remained unchanged.

There were no negative safety signals in postnatal outcomes of exposed children in terms of growth, psychomotor development, and the risk of allergy, atopy, or infectious complications.